This website uses cookies to ensure you get the best experience on our website.
Privacy Policy
I Agree
UroToday
Contact
Login
Sign Up Free
Transformative Evidence
mCRPC
PEACE-3 Trial
PROfound Trial
The RALU Study: Treatment Considerations in the First Line Setting of mCRPC
VISION Trial
mHSPC
ARANOTE Trial
ARASENS Trial
nmCRPC
ARAMIS Trial
nmCSPC
EMBARK Trial
PSMA PET Imaging
COBRA Trial
CONDOR Trial
OSPREY Trial
Bladder Cancer
Bladder Cancer Detection
CORE-001 Study
ADSTILADRIN
Centers of Excellence
Urologic Oncology
Left Group
Health Policy
Health Policy
Ruchika Talwar, MD
Bladder Cancer
Bladder Cancer
Ashish Kamat, MD
Advanced Bladder Cancer
Shilpa Gupta, MD
Trimodality Therapy
Leslie Ballas, MD
Kidney Cancer
Advanced Kidney Cancer
Pedro Barata, MD, MSc
Endourology
Endourology
Jaime Landman, MD
Prostate Cancer
Localized Prostate Cancer
Matthew R. Cooperberg, MD, MPH
Decipher Genomic Classifier
Imaging Center
Phillip Koo, MD
mHSPC
Neeraj Agarwal, FASCO, MD
nmCRPC
Zachary Klaassen, MD, MSc
mCRPC Treatment
A. Oliver Sartor, MD
PSMA-Targeted Therapy
Advanced Prostate Cancer
Zachary Klaassen, MD, MSc
Disparities: Social Determinants of Health
Disparities: Social Determinants of Health
Samuel L. Washington III, MD, MAS
Translational Prostate Cancer
Translational Science in Prostate Cancer
Andrea Miyahira, Ph.D
Women in Science
Andrea Miyahira, Ph.D
Upper Tract Urothelial Carcinoma
Upper Tract Urothelial Carcinoma
Sam S. Chang, MD, MBA
TESTICULAR, PENILE & RARE GU MALIGNANCIES
Testicular Cancer
Pelvic Health & Reconstruction
Bladder Health
Diane K. Newman, DNP, ANP-BC, FAAN
Pelvic Health
Diane K. Newman, DNP, ANP-BC, FAAN
Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction (SUFU)
Stephen R. Kraus, MD
Urologic Catheters (Includes CAUTI)
Diane K. Newman, DNP, ANP-BC, FAAN
Videos
Exclusives
Conferences
Exclusive Collaborations
Independent Medical Education
Covid-19
The Prostate Cancer Foundation
Health Policy in Urological Diseases
Disparities: Social Determinants of Health
Practice Guidelines Reviews
Urologic Oncology
Prostate Cancer
Bladder Cancer
Kidney Cancer
Upper Tract Urothelial Tumors
Testicular Cancer
Endourology
Pelvic Health & Reconstruction
Pelvic Health & Reconstruction
Trials in Progress
Trials in Progress
Bladder Cancer
IMMORTAL
PIVOT-006
Kidney Cancer
RadiCal
SAMURAI
Middle Side
Prostate Cancer
ARAMON
ARASEC
ARASTEP
CLARIFY
ECLIPSE
ESCAPE
FORT
Right Side
Prostate Cancer
Masofaniten (EPI-7386)
METANOVA
NRG-GU 0101
PROMISE
RTIRE
SECuRE
SHORTER
Clinical Trials
From the Editor
Search Clinical Trials
Articles
Urology (benign and malignant)
Urologic Oncology
Men's Health
Endourology & Stones
Pediatric Urology
COVID-19 and Genitourinary Cancers
Pelvic Health
Pelvic Health & Reconstruction
Conference Coverage
Recent Conferences
ASTRO 2024
IBCN 2024
ESMO 2024
BCAN TT 2024
ASCO 2024
All Conferences
View All
PCF
UroToday Home
Conference Highlights
ASCO 2022
ASCO 2022
Prostate Cancer
Bladder Cancer
Kidney Cancer
Testicular and Penile Cancer
Press Releases
ASCO 2022 Bladder Cancer
Viewing 1-20 of 35 articles
ASCO 2022: Preliminary Results of a Phase Ib/II Combination Study of RC48-ADC, a Novel Humanized Anti-HER2 Antibody-Drug Conjugate With Toripalimab, a Humanized IgG4 mAb Against PD-1 in Patients With Locally Advanced or Metastatic Urothelial Carcinoma
ASCO 2022: HER-2 Is New Again in Bladder Cancer - Discussion
ASCO 2022: Improving Outcomes Across the Stages in Bladder Cancer - Discussion
ASCO 2022: Long-Term Outcomes in EV-301: 24-Month Findings From the Phase 3 Trial of Enfortumab Vedotin Versus Chemotherapy in Patients With Previously Treated Advanced Urothelial Carcinoma
ASCO 2022: Perioperative Chemoimmunotherapy With Durvalumab for Operable Muscle-Invasive Urothelial Carcinoma: Primary Analysis of the Single Arm Phase II Trial SAKK 06/17
ASCO 2022: RC48-ADC For Metastatic Urothelial Carcinoma With HER2-Positive: Combined Analysis of RC48-C005 and RC48-C009 Trials
ASCO 2022: A Phase II Study of RC48-ADC in HER2-Negative Patients With Locally Advanced or Metastatic Urothelial Carcinoma
ASCO 2022: Avelumab As the Basis of Neoadjuvant Regimen in Platinum-Eligible and -Ineligible Patients With Nonmetastatic Muscle-Invasive Bladder Cancer: AURA (Oncodistinct-004) Trial
ASCO 2022: Long-Term Outcomes in Patients with Advanced Urothelial Carcinoma (UC) Who Received Avelumab First-Line Maintenance with or Without Second-Line Treatment: Exploratory Analyses from JAVELIN Bladder 100
ASCO 2022: Toripalimab (Anti-PD-1) Monotherapy as a Second-Line Treatment for Patients with Metastatic Urothelial Carcinoma (POLARIS-03): Two-Year Survival Update and Biomarker Analysis
ASCO 2022: Defining “Platinum-Ineligible” Patients with Metastatic Urothelial Cancer (mUC)
ASCO 2022: Preliminary Results from Phase Ib/II Neoadjuvant CG0070 and Nivolumab (N) for Cisplatin (C)-Ineligible Muscle Invasive Bladder Cancer (MIBC)
ASCO 2022: Association of DNA Damage Response Gene Mutations and Response to Neoadjuvant Cisplatin-Based Chemotherapy in MIBC Patients Enrolled Onto SWOG S1314
ASCO 2022: Interim Results from a Multicenter Clinical Study of Tislelizumab Combined with Gemcitabine and Cisplatin as Neoadjuvant Therapy for Patients with cT2-T4aN0M0 MIBC
ASCO 2022: Evaluating Oncologists’ Practice Patterns and Decision-Making in Locally Advanced or Metastatic Urothelial Carcinoma (la/mUC): The U.S. Physician PARADIGM Study (Part 2)
ASCO 2022: Avelumab First-Line (1L) Maintenance for Advanced Urothelial Carcinoma (aUC): Long-Term Outcomes from JAVELIN Bladder 100 in Subgroups Defined by Response to 1L Chemotherapy
ASCO 2022: Efficacy of Hyperthermic-Intra-Vesical Chemotherapy in Patients with BCG-Refractory Nonmuscle-Invasive Bladder Cancer
ASCO 2022: A Randomised, Double Blind, Phase II Clinical Trial of Maintenance Cabozantinib Following Chemotherapy for Metastatic Urothelial Carcinoma: Final Analysis of the ATLANTIS Cabozantinib Comparison
ASCO 2022: Real-World Treatment Patterns and Clinical Outcomes with First-Line Therapy in Cisplatin-Eligible and Ineligible Patients with Advanced Urothelial Carcinoma
ASCO 2022: A Phase 3 Study of the Subcutaneous Programmed Cell Death Protein 1 Inhibitor Sasanlimab as Single Agent for Patients with Bacillus Calmette-Guérin, Unresponsive High-Risk, Non-Muscle Invasive Bladder Cancer: CREST Study Cohort B
1
2
×
Login
Login to update email address, newsletter preferences and use bookmarks.
Email
Password
Login
Forgot Password?
Sign Up Free